Tirzepatide and oral contraceptives: the EMA committee's new advice

27 November 2026 · 3 min read · blogs.iictp.org/tirzepatide-oral-contraceptives-ema-advice

Short answer: tirzepatide may affect how reliably oral contraceptives work, and the European Medicines Agency's human medicines committee (CHMP) reported on 13 November 2026 that it had adopted a direct healthcare professional communication on Mounjaro. Women using an oral contraceptive are advised to add a barrier method for four weeks after starting and after each dose increase, or to switch to a non-oral method. It matters for anyone prescribing the medicine for diabetes or weight management.

TL;DR The short version

- The EMA's CHMP reported on 13 November 2026 a communication to health professionals that tirzepatide (Mounjaro) may affect how reliably oral contraceptives work.
- Women on an oral contraceptive are advised to add a barrier method for four weeks after starting and after each dose increase, or switch to a non-oral method.
- Prescribers and pharmacists should raise this when starting or increasing the dose; this summary is not clinical advice.

Read online, listen to it, or change the text size: https://blogs.iictp.org/tirzepatide-oral-contraceptives-ema-advice

What is the tirzepatide contraception advice?

Mounjaro (tirzepatide) is used with diet and physical activity for adults with type 2 diabetes that is not well controlled, and for weight management in people with obesity or with overweight and related conditions. The communication concerns its potential effect on the reliability of oral contraceptives and reminds professionals that contraception is recommended for women who can become pregnant and use the medicine.

What patients are advised to do

- Add a barrier method for four weeks after starting tirzepatide.
- Add a barrier method again for four weeks after each dose increase.
- Alternatively, switch to a non-oral method of contraception.

What is new in the advice

The highlight gives a concrete action tied to treatment timing. It states that information on the effect of tirzepatide on the pharmacokinetics and efficacy of oral contraceptives is limited in women with obesity, overweight or type 2 diabetes.

Other items from the same meeting

- The committee, meeting from 9 to 12 November, recommended seven medicines for marketing authorisation, including baxdrostat for insufficiently controlled hypertension and aumolertinib for non-small cell lung cancer.
- It recommended extending the indications of 11 medicines, including obinutuzumab for adults with moderate to severe active systemic lupus erythematosus.
- It confirmed refusal for two medicines after re-examination.

Limitations and open questions

- We read the meeting highlight, not the full communication or the product information.
- Evidence in the relevant patient groups is described as limited.
- The advice is European. Labelling in other countries may differ.
- A committee recommendation for a new medicine is not the same as availability where you practise.

Sources were read on 27 November 2026. Products, rules and data change, so check the linked originals before you rely on any detail.

How to apply it in clinic

1. Read the communication and the current product information.
2. Ask about contraception when starting tirzepatide and at every dose change.
3. Record the plan, either a time-limited barrier method or a non-oral method.
4. Add a prompt to the prescribing template and the pharmacy counselling checklist.
5. Review current users who take oral contraceptives.
6. Report suspected adverse reactions, including unplanned pregnancy, through your national system as appropriate.

What it means for prescribers and pharmacists

Dose escalation is when this advice is easiest to miss, because the visit focuses on tolerance and weight or glucose results. Build the question into the escalation step itself. Use plain language and give the four-week window in writing.

Frequently asked questions

- **Do tirzepatide and oral contraceptives interact?** The EMA committee flags a potential effect on reliability and advises extra or alternative contraception.
- **How long is a barrier method needed?** For four weeks after starting and for four weeks after each dose increase.
- **Is there another option?** Switching to a non-oral method.
- **Is the evidence complete?** No. The committee describes limited information in the relevant groups.

Related reading

- WHO type 1 diabetes guidelines for adults
- Factor XIa inhibitor stroke trial
- Smartwatch hypertension detection
- Certified Technical Practitioner

Related credential: Certified Technical Practitioner. Explore the exam facts and syllabus.

Sources and further reading

1. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026. 13 November 2026. ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026

Published by IICTP, an independent technical credential body, on 27 November 2026. The current version of this post is at https://blogs.iictp.org/tirzepatide-oral-contraceptives-ema-advice. More guides: blogs.iictp.org.